Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Total Liabilities (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Total Liabilities for 6 consecutive years, with $77.4 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 49.2% to $77.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $77.4 million through Dec 2025, down 49.2% year-over-year, with the annual reading at $77.4 million for FY2025, 49.2% down from the prior year.
  • Total Liabilities for Q4 2025 was $77.4 million at Lexicon Pharmaceuticals, down from $85.8 million in the prior quarter.
  • The five-year high for Total Liabilities was $174.6 million in Q1 2025, with the low at $74.7 million in Q1 2023.
  • Average Total Liabilities over 3 years is $122.4 million, with a median of $131.9 million recorded in 2023.
  • The sharpest move saw Total Liabilities skyrocketed 71.89% in 2024, then tumbled 49.2% in 2025.
  • Over 3 years, Total Liabilities stood at $136.3 million in 2023, then grew by 11.85% to $152.5 million in 2024, then crashed by 49.2% to $77.4 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $77.4 million, $85.8 million, and $96.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.